New drug cocktail targets Hard-to-Treat brain cancers

NCT ID NCT01107522

UNKNOWN_STATUS Disease control Sponsor: Tactical Therapeutics, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 1 time

Summary

This early-phase study tests an experimental drug called CTO, alone or combined with standard chemotherapy (Temodar) and radiation, in people with advanced solid tumors or glioblastoma (a type of brain cancer). The main goal is to find the safest dose and check for side effects. About 100 participants will be enrolled across three treatment groups.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Carboxyamidotriazole orotate (CTO) and temozolomide (Temodar)
What this could lead to: If successful, this could point toward a new combination treatment for glioblastoma and other advanced solid tumors.
What could go wrong: This is a very early Phase 1 trial with only 100 participants, focused on safety and dosing. It is too soon to know if the drug combination will effectively shrink tumors or improve survival.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

glioblastoma glioma malignant glioma metastatic malignant neoplasm neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

SOLID TUMORS, GLIOBLASTOMA, RECURRENT MALIGNANT GLIOMAS

Contacts and locations

Locations

Memorial Sloan-Kettering Cancer Center

New York, New York, 10017, United States
New York University

New York, New York, 10016, United States
Oregon Health and Sciences University

Portland, Oregon, 97239, United States
Providence Cancer Center

Portland, Oregon, 97213, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.